Orvepitant

DB12427InvestigationalSmall molecule

Orvepitant has been used in trials studying the treatment of Depressive Disorder, Depressive Disorder, Major, Post-Traumatic Stress Disorder, and Posttraumatic Stress Disorder (PTSD).

Mechanism: Pharmacologically active on Substance-P receptor
Curator reviewed
Formula / weight: C₃₁H₃₅F₇N₄O₂ · 628.636 g/mol (avg)
Code names: GW-823296X

Resolves to

Compound

UNIIIIU6V0W3JDCAS579475-18-6ChEMBLCHEMBL2105667PubChem9852175

Structure

InChIKeyXWNBGDJPEXZSQM-VZOBGQTKSA-NSMILESC[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1C1=CC=C(F)C=C1C)N1CCN2[C@@H](CCC2=O)C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F

Targets

P25103TACR1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

679Drug interactionsStructured to mechanism, not free text

8Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Orvepitant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account